

<b>INFORMATION DISCLOSURE STATEMENT LIST</b>  (Use as many sheets as necessary)	Complete if Known	
	Application Number	10/575,204
	Filing Date	April 10, 2006
	First Named Inventor	BARROW <i>et al.</i>
	Group Art Unit	Unassigned
	Examiner Name	Unassigned

U.S. PATENT DOCUMENTS							
Examiner's Initials	Cite No.	Document No.	Date	Name	Class	Subclass	Filing Date if appropriate
	C1	3,138,477	June 23, 1964	Torstenson <i>et al.</i>	117	36.1	
	C2	3,185,717	May 25, 1965	Trebilcock <i>et al.</i>	260	438	
	C3	3,260,689	July 12, 1966	Kibler <i>et al.</i>	260	22	
	C4	3,379,709	April 23, 1968	Louden <i>et al.</i>	260	103	
	C5	3,697,437	10/10/72	Fogel <i>et al.</i>	427	213.33	
	C6	3,887,390	June 3, 1975	Deiner	106	271	
	C7	3,983,270	September 28, 1979	Licari <i>et al.</i>	427	372	
	C8	4,010,038	3/1/78	Hinata <i>et al.</i>	430	550	
	C9	4,104,293	August 1, 1978	Redmore <i>et al.</i>	260	438.5	
	C10	4,218,385	August 19, 1980	Pike	260	408	
	C11	4,273,672	6/16/81	Vassiliades	264	4.1	
	C12	4,808,408	2/28/89	Backer <i>et al.</i>	424	408	
	C13	4,891,172	1/2/90	Matsushita <i>et al.</i>	264	4.33	
	C14	5,378,413	1/3/95	Mihm <i>et al.</i>	264	4.3	
	C15	5,700,397	12/23/97	Maeda <i>et al.</i>	428	402.24	
	C16	5,707,679	January 13, 1998	Nelson	426	635	
	C17	5,849,066	December 15, 1998	Kellett	106	31.13	
	C18	6,019,998	February 1, 2000	Nomoto <i>et al.</i>	424	400	
	C19	6,303,158	October 16, 2001	Odgaard	426	2	
	C20	2002/0031553	3/14/02	Moyano <i>et al.</i>	424	491	
	C21	2007/0059340	3/15/07	Belloe <i>et al.</i>	424	439	

FOREIGN PATENT DOCUMENTS					
Examiner's Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code	Date	Name	Translation Yes/No
	C22	CA 2,286,494	April 14, 2000	Luo <i>et al.</i>	
	C23	WO 2002/096408	May 12, 2002	Lax-Dale Ltd.	

NON-PATENT DOCUMENTS		
Examiner's Initials	Cite No.	Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Publication)
	C24	Amoiken <i>et al.</i> , "Effect of chromium tripicolinate on growth, glucose tolerance, insulin sensitivity, plasma metabolites, and growth hormone in pigs," <i>J. Amin. Sci.</i> 73:1123 (1995)
	C25	Barrow <i>et al.</i> , "Stablization of highly unsaturated fatty acids and delivery into foods," <i>Lipid Technology</i> , 9(5):108-111 (2007)
	C26	Boyle <i>et al.</i> , "Chromium depletion in the pathogenesis of diabetes and atherosclerosis," <i>Southern Med. J.</i> 70:1449-1453 (1977)
	C27	Fong, "Microencapsulation by solvent and organic phase separation processes," In "Controlled Release Systems: Fabrication Technology," Hsieh Ed., CRC Press, New York, pp. 99-105, 1988.

Examiner Signature:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

689413

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /D.D.O

## INFORMATION DISCLOSURE STATEMENT LIST

(Use as many sheets as necessary)

Complete if Known

Application Number	10/575,204
--------------------	------------

Filing Date	April 10, 2006
-------------	----------------

First Named Inventor	<b>BARROW et al.</b>
----------------------	----------------------

Group Art Unit	Unassigned
----------------	------------

Examiner Name	Unassigned
---------------	------------

[illegible]

Examiner Signature: /Deborah D Carr/

Date Considered: 05/05/2010

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.